Literature DB >> 28602761

Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum.

Alleyn T Plowright1, Christian Ottmann2, Michelle Arkin3, Yves P Auberson4, Henk Timmerman5, Herbert Waldmann6.   

Abstract

The scientific advances being made across all disciplines are creating ever-increasing opportunities to enhance our knowledge of biological systems and how they relate to human disease. One of the central driving forces in discovering new medicines is medicinal chemistry, where the design and synthesis of novel compounds has led to multiple drugs. Chemical biology, sitting at the interface of many disciplines, has now emerged as a major contributor to the understanding of biological systems and is becoming an integral part of drug discovery. Bringing chemistry and biology much closer and blurring the boundaries between disciplines is creating new opportunities to probe and understand biology; both disciplines play key roles and need to join forces and work together effectively to synergize their impact. The power of chemical biology will then reach its full potential and drive innovation, leading to the discovery of transformative medicines to treat patients. Advances in cancer biology and drug discovery highlight this potential.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; chemical biology; chemical probes; drug discovery; medicinal chemistry; phenotypic screening

Mesh:

Substances:

Year:  2017        PMID: 28602761     DOI: 10.1016/j.chembiol.2017.05.019

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  6 in total

Review 1.  Emerging modes-of-action in drug discovery.

Authors:  Eric Valeur; Frank Narjes; Christian Ottmann; Alleyn T Plowright
Journal:  Medchemcomm       Date:  2019-06-25       Impact factor: 3.597

2.  Gini Coefficients as a Single Value Metric to Define Chemical Probe Selectivity.

Authors:  Andrei Ursu; Jessica L Childs-Disney; Alicia J Angelbello; Matthew G Costales; Samantha M Meyer; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2020-07-09       Impact factor: 5.100

Review 3.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

4.  Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.

Authors:  Jing Tang; Zia-Ur-Rehman Tanoli; Balaguru Ravikumar; Zaid Alam; Anni Rebane; Markus Vähä-Koskela; Gopal Peddinti; Arjan J van Adrichem; Janica Wakkinen; Alok Jaiswal; Ella Karjalainen; Prson Gautam; Liye He; Elina Parri; Suleiman Khan; Abhishekh Gupta; Mehreen Ali; Laxman Yetukuri; Anna-Lena Gustavsson; Brinton Seashore-Ludlow; Anne Hersey; Andrew R Leach; John P Overington; Gretchen Repasky; Krister Wennerberg; Tero Aittokallio
Journal:  Cell Chem Biol       Date:  2017-12-21       Impact factor: 8.116

5.  (E)-2-Cyano-3-(1H-Indol-3-yl)-N-Phenylacrylamide, a Hybrid Compound Derived from Indomethacin and Paracetamol: Design, Synthesis and Evaluation of the Anti-Inflammatory Potential.

Authors:  Pablo Silva; Maria de Almeida; Jamire Silva; Sonaly Albino; Renan Espírito-Santo; Maria Lima; Cristiane Villarreal; Ricardo Moura; Vanda Santos
Journal:  Int J Mol Sci       Date:  2020-04-08       Impact factor: 5.923

6.  The structure of INI1/hSNF5 RPT1 and its interactions with the c-MYC:MAX heterodimer provide insights into the interplay between MYC and the SWI/SNF chromatin remodeling complex.

Authors:  Susan Sammak; Mark D Allen; Najoua Hamdani; Mark Bycroft; Giovanna Zinzalla
Journal:  FEBS J       Date:  2018-10-01       Impact factor: 5.542

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.